JW invests over 11% of its revenue in R&D, creating value that contributes to a healthier life for humanity through innovation. We place ethical and responsible management at the core of our operations, driving sustainable growth for the future.
In particular, JW’s proprietary R&D platform—spanning from original pharmaceuticals to innovative new drugs, built on strong technological capabilities—is the result of transparent decision-making and accountable management. It also demonstrates JW’s advanced governance system, including comprehensive risk management.
Through trustworthy and principled management for our customers and shareholders, JW aims to grow into a global leading healthcare company representing Korea.
ESG Ratings
ESG Ratings
| Category |
Integrated Rating |
E (Environment) |
S (Social) |
G (Governance) |
| 2025 |
B+ |
B+ |
A |
B+ |
| 2024 |
B+ |
B+ |
A |
B+ |
| 2023 |
B+ |
B |
A |
B+ |
※ Rating agency: Korea Institute of Corporate Governance and Sustainability (KCGS)
Corporate Governance Policies
Corporate Governance Policies
| No. |
Title |
Attachment |
| 1 |
Articles of Incorporation |
Download |
| 2 |
Board of Directors Regulations |
Download |
| 3 |
Audit Committee Regulations |
Download |
The Board of Directors of JW Pharmaceutical consists of a total of six members, including three executive directors and three independent directors, and operates an Audit Committee within the Board.
The independence of the independent directors has been verified in accordance with Article 382(3) and Article 542-8(2) of the Korean Commercial Act.
Board Composition
Board Composition
| Category |
Name |
Key Experience |
Appointment Date |
Term Expiration |
| Executive Director |
Young Sup Shin
(Chair) |
- B.A. in International Trade, Chung-Ang University
- Head of Pharmaceutical Business Division, JW Pharmaceutical
- Chief Executive Officer, JW Pharmaceutical
|
2023.03.29 |
2026.03.29 |
| Eun Kyung Ham |
- B.S. in Pharmacy, Seoul National University
- Chief Executive Officer, JW Bioscience
- Chief Executive Officer, JW Medical
- Chief Executive Officer, JW Pharmaceutical
|
2025.03.26 |
2028.03.26 |
| Kyung Ha Lee |
- College of Pharmacy, Sungkyunkwan University
- Chairman, JW Pharmaceutical
- Chairman, JW Holdings
|
2024.03.27 |
2027.03.27 |
| Independent Director |
Bo Sook Ahn |
- College of Pharmacy, Ewha Womans University
- Former Head of Pharmacy Department, Gangnam Severance Hospital
- Advisor, Junghun Pharmaceutical
|
2025.03.26 |
2028.03.26 |
| Woo Tak Lee |
- B.A. in Oriental History, Seoul National University
- Secretary General, Kwanhun Club
- Senior Journalist, Yonhap News Agency
|
2025.03.26 |
2028.03.26 |
| Gyu Eon Jung |
- Professor, School of Integrative Business, Korea University
- Former President, Korean Academic Society of Taxation
- Vice President, Korean Accounting Association
|
2023.03.29 |
2026.03.29 |
Material Resolutions of the Board of Directors
Material Resolutions of the Board of Directors
| No. |
Date |
Agenda Details |
Approval Result |
For/Against |
| 1 |
2025.02.11 |
1. Appointment of Compliance Officer
2. Approval of the 5th Revision to the CP Operating Regulations |
Approved |
For |
| 2 |
2025.02.11 |
Approval of the Convocation of the 69th Annual General Meeting of Shareholders and Meeting Agenda |
Approved |
For |
| 3 |
2025.03.06 |
Capital Conversion and Capital Increase for JW Euvipharm |
Approved |
For |
| 4 |
2025.03.24 |
Acquisition of Treasury Stock |
Approved |
For |
| 5 |
2025.04.17 |
Investment in ProGen Co., Ltd. |
Approved |
For |
| 6 |
2025.05.07 |
2025 2nd Regular Meeting of the Board of Directors |
Approved |
For |
| 7 |
2025.05.22 |
Execution of a Factoring Credit Line Agreement with a Financial Institution |
Approved |
For |
Audit Committee
JW Pharmaceutical has established an Audit Committee in accordance with Article 542-11 of the Korean Commercial Act and Article 37 of the Articles of Incorporation. The Committee’s operation, authority, and responsibilities are set forth in the Audit Committee Regulations.
Audit Committee Composition
Audit Committee Composition
| Name |
Outside Director Status |
Experience |
Accounting / Finance Expertise |
| Applicable |
Expert Type |
Relevant Experience |
| Bo Sook Ahn |
Yes |
- College of Pharmacy, Ewha Womans University
- Former Head of Pharmacy Department, Gangnam Severance Hospital
- Advisor, Junghun Pharmaceutical
|
- |
- |
- |
| Woo Tak Lee |
Yes |
- B.A. in Oriental History, Seoul National University
- Secretary General, Kwanhun Club
- Senior Journalist, Yonhap News Agency
|
- |
- |
- |
| Gyu Eon Jung |
Yes |
- Professor, School of Integrative Business, Korea University
- Former President, Korean Academic Society of Taxation
- Vice President, Korean Accounting Association
|
Yes |
Certified Public Accountant |
- |
Audit Committee Training
Audit Committee Training
| Training Date |
Attending Audit Committee Members |
Key Training Topics |
| 2025.07.31 |
All Members Present |
Corporate governance and the role of independent directors |
| 2025.07.31 |
All Members Present |
(New) Refresher course for Audit Committee School (2024)
- Accounting issues highlighted in the FSS review of financial statements |
Audit Committee Support Organization
Audit Committee Support Organization
| Division (Team) |
No. of Employees |
Position (Years of Service) |
Key Activities |
| Finance Team |
11 |
1 Team Leader, 10 Managers (Average: 6.4 years) |
Provision of Financial Information |
| Accounting Team |
7 |
1 Team Leader, 6 Managers (Average: 4.9 years) |
Provision of Accounting Information |
| Internal Control over Financial Reporting Team |
4 |
1 Team Leader, 3 Managers (Average: 1.2 years) |
Provision of Internal Accounting Control Information |
External Auditor
JW Pharmaceutical ensures the fairness and transparency of its accounting information through regular audits conducted by an independent external auditor.
Auditor's Opinion
Auditor's Opinion
| Fiscal Year |
Auditor |
Details |
Audit Opinion |
Total Hours |
Audit Fee |
| 69th Fiscal Year (2024) |
Ernst & Young Han Young |
2024 quarterly/semi-annual reviews and year-end audit |
Unqualified |
3,385 |
KRW 435 million |
| 68th Fiscal Year (2023) |
Ernst & Young Han Young |
2023 quarterly/semi-annual reviews and year-end audit |
Unqualified |
3,894 |
KRW 465 million |
| 67th Fiscal Year (2022) |
Ernst & Young Han Young |
2022 quarterly/semi-annual reviews and year-end audit |
Unqualified |
3,912 |
KRW 445 million |
| 66th Fiscal Year (2021) |
Ernst & Young Han Young |
2021 quarterly/semi-annual reviews and year-end audit |
Unqualified |
3,589 |
KRW 375 million |
Shareholder Composition
Shareholder Composition
| Shareholder |
No. of Shares Held |
Ownership Ratio |
Relationship with the Company |
| JW Holdings |
10,870,683 |
43.65% |
Parent Company |
| Treasury Stock |
744,166 |
2.99% |
|
| Other Shareholders |
13,286,540 |
53.36% |
|
Status of Total Shares
(As of June 30, 2025)(Unit: shares)
Status of Total Shares
| Category |
Type of Shares |
Remarks |
| Common Stock |
Preferred Stock |
Total |
| I. Total Number of Shares Authorized |
40,000,000 |
80,000,000 |
48,000,000 |
- |
| II. Total Number of Shares Issued to Date |
28,288,806 |
2,448,565 |
30,737,371 |
- |
| III. Total Number of Shares Reduced to Date |
5,002,876 |
833,106 |
5,835,982 |
- |
|
1. Capital Reduction |
- |
- |
- |
- |
|
2. Retirement of Shares from Earnings |
- |
428,420 |
428,420 |
Cancellation following the exercise of conversion rights for the 2nd and 3rd series of redeemable convertible preferred shares |
|
3. Redemption of Redeemable Shares |
- |
- |
- |
- |
|
4. Other |
5,002,876 |
404,686 |
5,407,562 |
Human spin-off and RCPS conversion to common stock |
| IV. Total Shares Outstanding (II - III) |
23,285,930 |
1,615,459 |
24,901,389 |
- |
| V. Treasury Shares |
736,412 |
7,754 |
744,166 |
- |
| VI. Shares in Circulation (IV - V) |
22,549,518 |
1,607,705 |
24,157,223 |
- |
Dividend Information
Dividend Information
| Category |
FY2020 |
FY2021 |
FY2022 |
FY2023 |
FY2024 |
| Par Value per Share (KRW) |
2,500 |
2,500 |
2,500 |
2,500 |
2,500 |
| Dividend per Share (KRW) |
Interim |
Common Stock |
- |
- |
- |
- |
- |
| Preferred Stock |
- |
- |
- |
- |
- |
| Year-end |
Common Stock |
325 |
325 |
375 |
400 |
450 |
| Preferred Stock |
350 |
350 |
400 |
425 |
475 |
| Total Dividend (KRW million) |
7,149 |
7,352 |
8,814 |
9,665 |
11,068 |
| Payout Ratio (%) |
- |
- |
- |
- |
- |
| Dividend Yield (%) |
Common Stock |
0.9 |
1.4 |
1.9 |
1.1 |
1.9 |
| Preferred Stock |
0.9 |
1 |
1.2 |
1.3 |
1.6 |
Voting Results by Agenda at the 69th Annual General Meeting of Shareholders (FY2024)
| Agenda |
Purpose of Meeting |
Resolution Type |
Approval Result |
Shares Present |
Votes in Favor |
Votes Against / Abstained |
Excluding the largest shareholder and related parties
attendance rate |
| Agenda 1 |
Approval of the 69th Fiscal Year Financial Statements and Consolidated Financial Statements |
Ordinary Resolution |
Approved |
15,429,196 |
15,214,009 |
215,187 |
28.41% |
| 98.60% |
1.40% |
| Agenda 2 |
Partial Amendment to the Articles of Incorporation |
Special Resolution |
Approved |
15,429,196 |
13,349,330 |
79,866 |
28.41% |
| 99.48% |
0.52% |
| Agenda 3-1 |
Appointment of Executive Director (Eun Kyung Ham) |
Ordinary Resolution |
Approved |
15,429,196 |
15,290,439 |
138,757 |
28.41% |
| 99.10% |
0.90% |
| Agenda 3-2 |
Appointment of Independent Director (Bo Sook Ahn) |
Ordinary Resolution |
Approved |
15,429,196 |
15,336,146 |
93,050 |
28.41% |
| 99.40% |
0.60% |
| Agenda 4 |
Appointment of Audit Committee Member (Bo Sook Ahn) |
Ordinary Resolution |
Approved |
15,429,196 |
5,193,999 |
93,050 |
82.90% |
| 98.24% |
1.76% |
| Agenda 5 |
Appointment of Independent Director Serving as Audit Committee Member (Woo Tak Lee) |
Ordinary Resolution |
Approved |
15,429,196 |
5,182,793 |
104,256 |
82.90% |
| 98.03% |
1.97% |
| Agenda 6 |
Approval of the Director Compensation Limit |
Ordinary Resolution |
Approved |
15,429,196 |
15,322,575 |
106,621 |
28.41% |
| 99.31% |
0.69% |